Breaking Finance News

equinet AG issued a report on Bayer (ETR:BAYN), raising its target price to 118.00EUR today

Showing a price of 90.62EUR, Bayer (ETR:BAYN) traded 0.00% even on the day. With the last stock price close up -9.38% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. BAYN has recorded a 50-day average of 0.04EUR and a two hundred day average of 0.03EUR. Trade Volume was down over the average, with 0 shares of BAYN changing hands under the typical 211

In a report released on Wednesday October 19, 2016 equinet AG bumped up the target of Bayer (ETR:BAYN) to 118.00EUR stating a potential upside of 0.30%.

On 10/18/2016, equinet AG released a statement on Bayer (ETR:BAYN) upped the target price from 0.00EUR to 118.00EUR that suggested an upside of 0.30%.

Recent Performance Chart

Bayer (ETR:BAYN)

Bayer has with a one year low of 0.01EUR and a one year high of 0.08EUR and has a market capitalization of 0 EUR.

General Company Details For Bayer (ETR:BAYN)

Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment is engaged in the development of prescription pharmaceuticals; contraceptives, and medical products, such as injection systems and contrast agents for diagnostic procedures. The Consumer Health segment is engaged in the development of over-the-counter medications, dermatology products and nutritional supplements. The Crop Science segment is engaged in the development of product portfolio in the areas of seeds and plant traits, crop protection, home and garden, the green industry and nonagricultural pest control. The Animal Health segment is engaged in the development of veterinary medicines and animal grooming products. Covestro is engaged in the development of raw materials for polyurethanes; polycarbonate resins and sheets; raw materials for coatings, adhesives and sealants; and selected chemical intermediates.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *